Amsterdam, 30th January 2017: CPhI Istanbul – organised by Ubm emea in partnership with Pharmaceutical Manufacturers Association of Turkey (IEIS) – returns to Turkey for its fourth edition with a new co-located event, BioPh to join ICSE, P-MEC and InnoPack. Taking place 8-10th March 2017, the five-in-one event is expected to bring together over 4500 pharma industry leaders from 82 countries and 236 exhibitors.
This year, the MENA region’s most prestigious pharma show is housed in a new venue – the Istanbul Expo Centre (IFM) – as CPhI Istanbul sees a huge 72% increase in floor space and exhibitors since its inauguration.
A rapidly emerging MENA biologics industry in both Turkey and the wider region sees key trends in biopharmaceutical, biosimilars and biobetters debated. With the goal of developing Turkey as an R&D and technology hub, the Government has put place a number of measures to stimulate expansion of biotechnology and biopharmaceutical activities. For example, incentive schemes covering as much as 50% of expenditures related to biopharm R&D, and many Turkish pharma manufacturers are seeing this as a major new revenue stream.
The Biopharma conference launching at CPhI Istanbul is being undertaken with the full backing of local and national Government. It will see three days of content-led sessions and 300 speakers and delegates discuss the opportunities for companies in Turkey and the MENA region. The conference includes educational and analytical sessions on IP security, regulatory procedures and market strategies; as well as the future of biosimilars, clinical trials and R&D in the area.
Orhan Caglayan, Brand Director CPhI Istanbul at Ubm emea, commented: “The Turkish pharma industry has grown a robust rate in the last few years and the return for the 4th edition of CPhI Istanbul incorporating BioPh, is opening many new opportunities for this domestic market and for regional exports. Turkey is now the fastest growing economy in the OCED and already posses the 8th largest pharma market in Europe. Biologics and biotechnology are now emerging as key trends alongside the industry’s core strengths in ingredients and solid dose drugs, where we have seen a steady rise in exhibitors.”
Moreover, in the past, 50% of the pharma industry relied on imports, but increasingly both the government and manufacturers are looking to source local ingredients, which is driving increased interest for CPhI Istanbul. There are 80+ production facilities, with export markets for both ingredients and finished dose in central Asia and the Middle East. To help navigate these options CPhI Istanbul will also include several Roundtable discussions – with a panel of analysts, consultants, regulators, pharma companies and experts – on the ‘drug registration processes’, ‘marketing channels’, ‘pricing and reimbursement’, and ‘business culture and economic outlook’ amongst others.
